Jones Mark, Goodyear Ross L
Liverpool ChiroChem Ltd, The Heath Business & Technical Park, Runcorn, Cheshire WA7 4QX, U.K.
ACS Med Chem Lett. 2023 May 31;14(7):916-919. doi: 10.1021/acsmedchemlett.3c00073. eCollection 2023 Jul 13.
With the "low hanging fruit" of early drug discovery gone, pharmaceutical companies are increasingly turning to developing high-throughput synthetic platforms capable of greatly shortening the design-make-test cycle of new drugs. Purification has long been considered the bottleneck of this procedure; however, new technologies and systems are now being integrated into these high-throughput synthetic workflows, providing compounds of high purity capable of being used directly in biological screening.
随着早期药物发现的“低垂果实”逐渐减少,制药公司越来越多地转向开发能够大幅缩短新药设计-制造-测试周期的高通量合成平台。长期以来,纯化一直被视为这一过程的瓶颈;然而,新技术和系统现在正被整合到这些高通量合成工作流程中,从而提供能够直接用于生物筛选的高纯度化合物。